TY - JOUR
T1 - Vaccination strategies in lymphomas and leukaemias
T2 - Recent progress
AU - Rezvani, Katayoun
AU - De Lavallade, Hugues
N1 - Funding Information:
This work was supported by the Kay Kendall Leukemia Fund (grant no. KKL 314), Institut National du Cancer (INCa) and Marie Curie International Reintegration Grant (IRG 224957). We acknowledge the support of the National Institute for Health Research (NIHR), Biomedical Research Center (BRC). The authors have no conflicts of interest that are directly related to the content of this review.
PY - 2011
Y1 - 2011
N2 - The successful identification of a range of leukaemia-specific and lymphoma-specific antigens in recent years has stimulated efforts to develop therapeutic vaccination strategies. A number of clinical trials have established the safety and immunogenicity of vaccination against tumour antigens, although there are limited data on the clinical efficacy of this approach in haematological malignancies. After encouraging results of phase III trials using idiotype vaccines in lymphoma, the outcome of the three phase III trials has been somewhat disappointing. Several other promising strategies are currently being developed to improve these results, including optimization of antigen delivery. In myeloid leukaemias, clinical trials of vaccination with peptides derived from a number of leukaemia antigens, including WT1, PR1, RHAMM and BCR-ABL, have shown evidence of immunogenicity, but limited data are available on the clinical efficacy of this approach. In this review, we focus on the results of clinical trials of vaccination in leukaemia and lymphoma, and discuss potential strategies to enhance the efficacy of immunotherapy in the future.
AB - The successful identification of a range of leukaemia-specific and lymphoma-specific antigens in recent years has stimulated efforts to develop therapeutic vaccination strategies. A number of clinical trials have established the safety and immunogenicity of vaccination against tumour antigens, although there are limited data on the clinical efficacy of this approach in haematological malignancies. After encouraging results of phase III trials using idiotype vaccines in lymphoma, the outcome of the three phase III trials has been somewhat disappointing. Several other promising strategies are currently being developed to improve these results, including optimization of antigen delivery. In myeloid leukaemias, clinical trials of vaccination with peptides derived from a number of leukaemia antigens, including WT1, PR1, RHAMM and BCR-ABL, have shown evidence of immunogenicity, but limited data are available on the clinical efficacy of this approach. In this review, we focus on the results of clinical trials of vaccination in leukaemia and lymphoma, and discuss potential strategies to enhance the efficacy of immunotherapy in the future.
KW - Cancer-vaccines
KW - Leukaemia
KW - Lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=80052634772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052634772&partnerID=8YFLogxK
U2 - 10.2165/11593270-000000000-00000
DO - 10.2165/11593270-000000000-00000
M3 - Review article
C2 - 21902290
AN - SCOPUS:80052634772
SN - 0012-6667
VL - 71
SP - 1659
EP - 1674
JO - Drugs
JF - Drugs
IS - 13
ER -